eprintid: 10172369
rev_number: 7
eprint_status: archive
userid: 699
dir: disk0/10/17/23/69
datestamp: 2023-06-26 10:28:04
lastmod: 2023-06-26 10:28:04
status_changed: 2023-06-26 10:28:04
type: article
metadata_visibility: show
sword_depositor: 699
creators_name: El-Agnaf, O
creators_name: Bensmail, I
creators_name: Al-Nesf, MAY
creators_name: Flynn, J
creators_name: Taylor, M
creators_name: Majbour, NK
creators_name: Abdi, IY
creators_name: Vaikath, NN
creators_name: Farooq, A
creators_name: Vemulapalli, PB
creators_name: Schmidt, F
creators_name: Ouararhni, K
creators_name: Al-Siddiqi, HH
creators_name: Arredouani, A
creators_name: Wijten, P
creators_name: Al-Maadheed, M
creators_name: Mohamed-Ali, V
creators_name: Decock, J
creators_name: Abdesselem, HB
title: Uncovering a neurological protein signature for severe COVID-19
ispublished: pub
divisions: UCL
divisions: B02
divisions: C10
divisions: D17
keywords: Severe COVID-19, Neurological complications, Olink proteomics, Protein signature
note: © 2023 The Author(s). Published by Elsevier Inc. under a Creative Commons license (http://creativecommons.org/licenses/by/4.0/).
abstract: Coronavirus disease of 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has sparked a global pandemic with severe complications and high morbidity rate. Neurological symptoms in COVID-19 patients, and neurological sequelae post COVID-19 recovery have been extensively reported. Yet, neurological molecular signature and signaling pathways that are affected in the central nervous system (CNS) of COVID-19 severe patients remain still unknown and need to be identified. Plasma samples from 49 severe COVID-19 patients, 50 mild COVID-19 patients, and 40 healthy controls were subjected to Olink proteomics analysis of 184 CNS-enriched proteins. By using a multi-approach bioinformatics analysis, we identified a 34-neurological protein signature for COVID-19 severity and unveiled dysregulated neurological pathways in severe cases. Here, we identified a new neurological protein signature for severe COVID-19 that was validated in different independent cohorts using blood and postmortem brain samples and shown to correlate with neurological diseases and pharmacological drugs. This protein signature could potentially aid the development of prognostic and diagnostic tools for neurological complications in post-COVID-19 convalescent patients with long term neurological sequelae.
date: 2023
date_type: published
publisher: Elsevier BV
official_url: https://doi.org/10.1016/j.nbd.2023.106147
oa_status: green
full_text_type: pub
language: eng
primo: open
primo_central: open_green
verified: verified_manual
elements_id: 2023129
doi: 10.1016/j.nbd.2023.106147
medium: Print-Electronic
pii: S0969-9961(23)00161-4
lyricists_name: Mohamed Ali, Vidya
lyricists_name: Al-Mansouri, Maryam
lyricists_id: VMOHA48
lyricists_id: MAAAL15
actors_name: Al-Mansouri, Maryam
actors_id: MAAAL15
actors_role: owner
funding_acknowledgements: [Qatar Biomedical Research Institute]; MRC-05-003 [Hamad Medical Corporation]
full_text_status: public
publication: Neurobiology of Disease
volume: 182
article_number: 106147
event_location: United States
citation:        El-Agnaf, O;    Bensmail, I;    Al-Nesf, MAY;    Flynn, J;    Taylor, M;    Majbour, NK;    Abdi, IY;                                                 ... Abdesselem, HB; + view all <#>        El-Agnaf, O;  Bensmail, I;  Al-Nesf, MAY;  Flynn, J;  Taylor, M;  Majbour, NK;  Abdi, IY;  Vaikath, NN;  Farooq, A;  Vemulapalli, PB;  Schmidt, F;  Ouararhni, K;  Al-Siddiqi, HH;  Arredouani, A;  Wijten, P;  Al-Maadheed, M;  Mohamed-Ali, V;  Decock, J;  Abdesselem, HB;   - view fewer <#>    (2023)    Uncovering a neurological protein signature for severe COVID-19.                   Neurobiology of Disease , 182     , Article 106147.  10.1016/j.nbd.2023.106147 <https://doi.org/10.1016/j.nbd.2023.106147>.       Green open access   
 
document_url: https://discovery.ucl.ac.uk/id/eprint/10172369/1/Uncovering%20a%20neurological%20protein%20signature%20for%20severe%20COVID-19.pdf